In a competitive market, brands rely on their reputations to give them an edge. However, these reputations are built on perceptions — and because it’s up to consumers to develop their own perceptions, brands may feel as though they have less control in developing lasting loyalty. This is especially true in the pharmaceutical industry due to where pharmaceutical manufacturers reside within healthcare’s value chain. In the patient-doctor relationship, pharmaceutical companies are the left-out third wheel.

Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.

All of the world’s top 10 pharmaceutical companies have established substantial operations in Ireland and from 2003 to today, there has been dynamic growth of biologics manufacturing in Ireland, according to IDA Ireland.

Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

A bill to encourage the manufacture of active pharmaceutical ingredients in America was introduced in the U.S. Senate by Senators Marsha Blackburn (R-TN) and Bob Menendez (R-NJ).

The U.S. Department of Health and Human Services is investigating a manufacturing defect in some initial coronavirus test kits that prompted some states to seek emergency approval to use their own test kits.

As part of Fingerpaint’s continued commitment to bring forward the best opportunities to their clients, the full-service health and wellness marketing agency acquired 1798, a market access and commercialization firm located in La Jolla, Calif.

The U.S. Food and Drug Administration declined to approve Enzyvant’s regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about the privately held drug developer’s manufacturing.

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines.

Teva Pharmaceuticals has done an about-face and will resume production of the company’s generic chemotherapy drug vincristine, which has been described as a “lynchpin” in the treatment of many childhood cancers.